MannKind (MNKD +7.1%) trades higher with more chatter swirling that it will take on a partner to...


MannKind (MNKD +7.1%) trades higher with more chatter swirling that it will take on a partner to help get it over the hump. Shares touched $2.60 in intra-day trading for the first time since late July.
From other sites
Comments (1)
  • capbaron
    , contributor
    Comments (2) | Send Message
     
    Have been following Mannkind and Al Mann companies for several years. He is a very interesting person and became a self made billionarie mostly from building companies in the bio-med industry. Before you invest in Mannkind you need to understand Mr. Mann, he is a proven entity and can make you a lot of money. It's hard to find out about all of his companies, because most of them are privately held, what his true net worth is and how much cash he can raise.
    The thing that amazes me the most is that the delivery system that Mannkind has developed can be used and is being test on various other drugs for cancer, and pain management.
    27 Aug 2012, 03:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs